Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss (GENERA)

Inclusion Criteria: Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms; Age greater than 18 and equal or under 50 years; Confirmed diagnosis of female pattern hair loss, grade II to IV in Sinclair Scale; Participants that are disposed to maintain the same hair color, style, approximate hair length throughout the Clinical Study. Exclusion Criteria: Any clinical or physical finding interpreted by the investigator as a risk to subject participation in the Clinical Study History of alcohol or illicit drugs abuse in the last year; Pregnant or breastfeeding women, who are planning to become pregnant or participants who have childbearing potential and are not using any reliable contraceptive method; Allergy or sensibility to any knowing components of the formula; Diagnosis of arterial hypertension; History of vasovagal syncope; Baseline systolic blood pressure lower than 90 mmHg and/or diastolic lower than 60 mmHg; Diagnosis of orthostatic hypotension (reduction of systolic blood pressure equal or superior to 20 mmHg and/or diastolic equal or superior to 10 mmHg after 3 minutes in orthostatic position); Body mass index (BMI) > 30 kg/m²; Subjects that initiated any kind of continue use medication, including contraceptives with systemic effect, until 3 months previously the inclusion in the Clinical Study; History of cardiovascular, liver and renal diseases; History of hypothyroidism, hyperthyroidism or pheochromocytoma; Signs or symptoms of cardiopathy or angina; History of edema from any etiology; Participants who are using tricycle antidepressants, benzodiazepines, antipsychotics, anticholinergics, sulfonamide derivatives, beta-blockers, sympathomimetics, arginine, glucocorticoid or monoamine oxidase inhibitors; Use of inhibitor of 5-alpha reductase or androgenic blockers in the last 12 months; Dermatologic diseases of the scalp, except mild seborrheic dermatitis or diagnosis of any kind of alopecia other than female pattern hair loss; History of surgical treatment for hair loss or presence of shaved scalp; Scalp microinfusion, microneedling or intradermotherapy in the last 3 years; Vaginal or cesarean deliveries 6 months before the inclusion in the study; Drastic modification of habitual diet, as food restrictions or hyperselectivity; Current cancer or history of cancer in the last 5 years; Participation in others research protocols in the last 12 months, unless the investigator judges that there may be a direct benefit to the participant.